Neurogene Inc. (NGNE) earnings date
Mar 22, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 19 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Tue, Mar 24, 2026 | before open | 83 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | after close | 44 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | after close | 42 | 8-K |
| Q1 FY2025 | Fri, May 9, 2025 | before open | 39 | 8-K |
| Q4 FY2024 | Mon, Mar 24, 2025 | after close | 83 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates Topline data from Embolden™ registrational trial anticipated in 2H 2027 Presented new preclinical data highlighting the purposeful design of NGN-401 for Rett syndrome, including rapid onset and durable expression of full-length MECP2 transgene with single-stranded AAV construct NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of November 8, 2026 On track to complete PPQ runs by year-end 2026 Strong cash position provides runway into first quarter of 2029 NEW Y" exhibit |
| Q3 FY2026 | "“With topline data from the Embolden registrational trial expected in the second half of 2027, we are progressing key BLA and commercial-readiness activities, including PPQ runs that we believe remain on track for completion this year." exhibit |
| Q3 FY2026 | "Anticipate reporting topline data from the Embolden™ registrational trial in the second half of 2027 o As previously announced, the Embolden trial was overenrolled due to strong demand from the Rett syndrome community." exhibit |
| Q3 FY2026 | "On track to complete Process Performance Qualification (PPQ) runs by the end of 2026 to support the planned Biologics License Application (BLA) submission Key Anticipated NGN-401 Milestones" exhibit |
| Q3 FY2026 | "Cash, Cash Equivalents and Short-Term Investments : Cash, cash equivalents and short-term investments as of September 30, 2026 were $359.7 million and are expected to fund planned operations into the first quarter of 2029." exhibit |
| Q2 FY2026 | "Document Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026 Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment Topline data from Embolden™ registrational trial anticipated in 2H 2027 NGN-401 at the 1E15 vg dose remains generally we" exhibit |
| Q2 FY2026 | "“The clinically meaningful benefit observed across all participants, including 100% of treated participants improving on CGI-I and gaining an average of 4.7 developmental milestones, strengthens our confidence in the program as we advance toward topline Embolden™ registrational data, which are expected in the second half of 2027." exhibit |
| Q2 FY2026 | "Announced today the Process Performance Qualification (PPQ) campaign was initiated in July 2026 to support planned Biologics License Application (BLA) submission; completion of PPQ runs expected by the end of 2026" exhibit |
| Q2 FY2026 | "Together with approximately $134.8 million of net proceeds received from our July 2, 2026 public offering, Neurogene had pro forma cash, cash equivalents and short-term investments of approximately $360.2 million and expect its current cash resources to fund planned operations into the first quarter of 2029." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NGNE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NGNE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/NGNE/"><img src="https://veritasdata.dev/embed/NGNE.svg" alt="NGNE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/NGNE/)
Script
<script async src="https://veritasdata.dev/embed/NGNE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NGNE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.